NAM
WST icon

Nissay Asset Management’s West Pharmaceutical WST Stock Holding History

Nissay Asset Management’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.66M Buy
10,197
+395
+4% +$121K 0.02% 418
2026
Q1 		$2.46M Buy
9,802
+190
+2% +$47.3K 0.01% 456
2025
Q4 		$2.64M Sell
9,612
-188
-2% -$51.4K 0.01% 446
2025
Q3 		$2.57M Sell
9,800
-71
-0.7% -$17.3K 0.01% 447
2025
Q2 		$2.16M Buy
9,871
+509
+5% +$109K 0.01% 494
2025
Q1 		$2.1M Buy
9,362
+44
+0.5% +$12.1K 0.01% 503
2024
Q4 		$3.1M Buy
9,318
+55
+0.6% +$17.3K 0.02% 416
2024
Q3 		$2.78M Buy
9,263
+257
+3% +$78.7K 0.02% 446
2024
Q2 		$2.97M Buy
9,006
+91
+1% +$32.2K 0.02% 405
2024
Q1 		$3.53M Buy
8,915
+263
+3% +$97.3K 0.02% 372
2023
Q4 		$3.05M Buy
8,652
+446
+5% +$158K 0.02% 365
2023
Q3 		$3.08M Buy
8,206
+227
+3% +$87.8K 0.03% 334
2023
Q2 		$3.05M Sell
7,979
-74
-0.9% -$26.4K 0.03% 349
2023
Q1 		$2.79M Sell
8,053
-259
-3% -$75.7K 0.02% 361
2022
Q4 		$1.96M Sell
8,312
-270
-3% -$64K 0.02% 444
2022
Q3 		$2.11M Buy
8,582
+249
+3% +$75.9K 0.02% 408
2022
Q2 		$2.52M Sell
8,333
-4,263
-34% -$1.39M 0.03% 357
2022
Q1 		$5.17M Sell
12,596
-1,377
-10% -$539K 0.05% 244
2021
Q4 		$6.55M Buy
13,973
+250
+2% +$108K 0.05% 212
2021
Q3 		$5.83M Buy
13,723
+238
+2% +$100K 0.05% 214
2021
Q2 		$4.84M Sell
13,485
-3,684
-21% -$1.22M 0.04% 241
2021
Q1 		$4.84M Buy
17,169
+4,698
+38% +$1.34M 0.05% 226
2020
Q4 		$3.53M Buy
12,471
+142
+1% +$39.8K 0.05% 275
2020
Q3 		$3.39M Sell
12,329
-9,744
-44% -$2.58M 0.06% 244
2020
Q2 		$5.01M Buy
22,073
+4,753
+27% +$934K 0.1% 199
2020
Q1 		$2.64M Buy
17,320
+10,799
+166% +$1.66M 0.07% 269
2019
Q4 		$980K Buy
+6,521
New +$949K 0.02% 530

Other funds holding WST

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Nissay Asset Management's WST Position: Q2 2026 in Review

Nissay Asset Management increased its West Pharmaceutical (WST) stake by 4% in Q2 2026, buying an estimated $121K and bringing the position to 10,197 shares worth $3.66M. The position accounts for 0.02% of the portfolio, ranked #418.

Nissay Asset Management first reported a position in WST in Q4 2019 and has held it in 27 quarters since. The position peaked at $6.55M in Q4 2021. 831 funds tracked by Wall St. Rank hold WST as of Q2 2026.

  • Nissay Asset Management held 10,197 shares of West Pharmaceutical worth $3.66M as of Q2 2026.
  • Nissay Asset Management bought 395 West Pharmaceutical shares in Q2 2026, an estimated $121K.
  • West Pharmaceutical made up 0.02% of Nissay Asset Management's portfolio in Q2 2026, its #418 holding.
  • Nissay Asset Management first reported a position in West Pharmaceutical in Q4 2019 and has held it in 27 quarters since.
  • Nissay Asset Management's West Pharmaceutical position peaked at $6.55M in Q4 2021.
  • 831 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2026.

Based on Nissay Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.